IL-17 Inhibitors: Secukinumab, Ixekizumab, Brodalumab
IL-17 inhibitors, including Secukinumab, Ixekizumab, and Brodalumab, are monoclonal antibodies targeting interleukin-17, a cytokine involved in inflammatory processes. These agents are primarily used for treating psoriasis and other autoimmune conditions, offering significant improvements in disease severity and quality of life for patients.
Topics: IL-17, biologics, psoriasis
Overview / Definition IL-17 inhibitors are a class of biologic medications that target the interleukin-17 (IL-17) pathway, which plays a crucial role in the pathogenesis of several inflammatory and autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. By inhibiting IL-17, these agents reduce the inflammatory response, leading to decreased skin and joint symptoms. Epidemiology Psoriasis affects approximately 2-3% of the global population, with a significant prevalence in adults aged 20-50. The incidence of psoriatic arthritis in patients with psoriasis ranges from 10-30%. IL-17 inhibitors have been developed in response to the unmet needs of patients who are non-responders to traditional systemic therapies. Pathophysiology / Mechanism IL-17 is a pro-inflammatory cytokine produced primarily by Th17 cells, which are a subset of CD4+ T lymphocytes. In psoriasis, IL-17 contributes to keratinocyte proliferation, angiogenesis, and inflammation. The mechanism of action of IL-17 inhibitors includes: Neutralization of IL-17A (Secukinumab, Ixekizumab) Neutralization of IL-17RA (Brodalumab) Reduction of downstream inflammatory mediators Clinical Presentation Patients with psoriasis often present with: Red, scaly plaques on extensor surfaces, scalp, and lower back Pruritus and discomfort Nail changes such as pitting or onycholysis Joint pain or swelling in psoriatic arthritis It is essential to evaluate the severity of the disease using tools like the Psoriasis Area and Severity Index (PASI) and assess the impact on the patient's quality of life. Diagnosis / Workup The diagnosis of psoriasis is primarily clinical, based on characteristic findings. However, the following steps may be involved in the workup: Clinical history and physical examination Skin biopsy (if atypical presentation or for differential diagnosis) Laboratory tests (e.g., complete blood count, liver function tests) to assess comorbidities Conditions to differentiate include e